Research lines

GSK-3 Inhibitors

Glycogen synthse kinase 3 (GSK-3) is a Ser/Thr kinase involved in many cellular signaling processes. Although it is known since more than thirty years ago to be the last enzyme in the glycogen synthesis pathway, nowadays GSK-3 emerged as an important target for unmet diseases such as Alzheimer's disease, diabetes type II, cancer and chronic inflammatory diseases. In these pathologies, an increase on GSK-3 activity has been reported. Thus, the use of its inhibitors is one of the most promising therapeutic strategies for the future treatment of these severe diseases.

Our research group has a vast experience on GSK-3 inhibitors, being the first ones in describe ATP non-competitive GSK-3 inhibitors. One chemical family of our compounds, known as TDZDs, has been worldwide licensed to NOSCIRA and currently one candidate called NP-12 is on clinical trials (phase II) as a disease modifying agent for Alzheimer's disease.

This fruitful line of research goes on in our group aiming to discover new selective and ATP non-competitive GSK-3 inhibitors with drug-like properties and the evaluation of their therapeutic potential neurodegeneratives pathologies such as ParkinsonĀ“s disease, multiple sclerosis and amyotrophic lateral sclerosis.


Maria Teresa Solas, PhD, Facultad de Biologia, Universidad Complutense. Madrid (Spain)

Carmen Guaza, PhD, Instituto de Neurobiologia Ramón y Cajal-CSIC. Madrid (Spain)

Francisca Vicente, PhD, Fundación Medina. Granada (Spain)

Francisco Wandosell, PhD, Centro de Biologia Molecular-CSIC. Madrid (Spain)

Hugo Cerecetto, PhD, Universidad de la Republica del Uruguay, Montevideo (Uruguay)

Luis Barbeito, PhD, Instituto Pasteur, Montevideo (Uruguay)